PointState Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

PointState Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-400,000	Closed	-$12.1M	–	121
2015 Q4	$12.1M	Buy	+400,000	New	+$12.9M	0.31%	47
2015 Q3	–	Sell	-300,000	Closed	-$20.7M	–	151
2015 Q2	$20.7M	Sell	300,000 -450,000	-60%	-$28.3M	0.24%	69
2015 Q1	$41M	Buy	750,000 +440,000	+142%	+$21M	0.55%	44
2014 Q4	$13.2M	Buy	310,000 +250,000	+417%	+$9.03M	0.23%	73
2014 Q3	$1.92M	Buy	+60,000	New	+$1.28M	0.03%	87

Other funds holding AMAG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIM

Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return

PointState Capital's AMAG Position: Q1 2016 in Review

PointState Capital sold out of AMAG Pharmaceuticals (AMAG) in Q1 2016, closing a stake of 400,000 shares — an estimated $12.1M sold.

PointState Capital first reported a position in AMAG in Q3 2014 and held it in 5 quarters. The position peaked at $41M in Q1 2015. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2016.

PointState Capital reported no remaining AMAG Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
PointState Capital sold 400,000 AMAG Pharmaceuticals shares in Q1 2016, an estimated $12.1M.
PointState Capital first reported a position in AMAG Pharmaceuticals in Q3 2014 and held it in 5 quarters.
PointState Capital's AMAG Pharmaceuticals position peaked at $41M in Q1 2015.
185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2016.

Based on PointState Capital's 13F filing for Q1 2016, filed 16 May 2016.